Share this Job

Senior Medical Advisor

Requistion ID:  2353

Copenhagen, Hovedstaden, DK

Date:  13-Oct-2021

Global Senior Medical Advisor - Aripiprazole & Brexpiprazole, Medical Strategy & Communication


Lundbeck’s passion links to our purpose about restoring brain health so every person can be their best. We strive to make a real difference to patients. By developing innovative treatments, we improve the lives of people living with brain diseases. Your dedication is crucial. That is why you can expect us to be committed to your progress, so you can stay committed to ours.


We offer an opportunity to join a global pharmaceutical company and to lead international medical activities for our products and related disease areas. The position is based at our headquarters in Copenhagen, reporting to Director, Aripiprazole & Brexpiprazole, Medical Strategy & Communication.


The Aripiprazole & Brexpiprazole team consists of 4 specialists and one operations manager. The team is responsible for all international medical activities for brexpiprazole and long-acting injectable formulations of aripiprazole, including (1) leading the development of the scientific communication strategy, and driving evidence generation strategies and publication plans; (2) conducting advisory meetings with medical experts, symposia at conferences, and disease and product training; (3) reviewing promotional materials and regulatory documents; and (4) supporting affiliates and other functions in Lundbeck in our joint effort to address patient needs.


Your job and key responsibilities


You will focus brexpiprazole, developed and marketed jointly with our partner Otsuka. In your global role, you will contribute to developing the brand strategy, and support the affiliates with its implementation in their country.


Brexpiprazole was first approved for the treatment of schizophrenia and adjunct treatment in MDD in the US in 2015. Today it is approved in several markets, either for both indications (Canada, Chile, Mexico, Saudi Arabia) or for treatment of schizophrenia (EU, Australia, Japan). Additional markets are expecting regulatory approval, and we are in launch phase in several countries around the globe.

Within the approved indications, further studies are ongoing to broaden the knowledge of the use and effectiveness of brexpiprazole. Furthermore, we are planning for additional indications (agitation in Alzheimer’s disease and post-traumatic stress disorder) and are currently conducting Phase 3 clinical trials to investigate the effects of brexpiprazole in these.


Your main tasks will be to lead medical education activities related to brexpiprazole in MDD and schizophrenia and to plan and execute key medical activities to support the launch in the new indications. You are expected to drive the scientific dialogue, secure effective collaboration and communication with external experts and maintain strong collaboration with internal stakeholders from Marketing, Market Access, Clinical Development, Value Evidence and other functional areas, as well as our Otsuka counterparts.

You are expected to travel about 20-30 days per year to cover meetings and international congresses.

As you will be creating new medical materials as well as reviewing promotional materials, it is critical for your role to ensure compliance to industry codes and regulations.



Our preferred candidate has the following qualifications:

  • An advanced academic degree in natural sciences (MD or PhD)
  • Experience from pharmaceutical medical affairs/drug development
  • Experience from psychiatry research or clinical practice


In addition, you are a strong team player, used to drive projects from start to end with focus on deadlines, and you truly enjoy strategic thinking and tactical planning. You have analytical skills and can prioritize effectively in a dynamic and at times hectic environment. You are motivated by applying and further developing expertise to achieve work objectives and are fluent in English and can communicate effectively internally and externally.


Further information

For further information, please contact Director, MSC Aripiprazole & Brexpiprazole, Stine Rasmussen Meehan at smer@lundbeck.com. Please do not send application or CV over email.

We recommend that you visit our website www.lundbeck.com.


Your application

Please click on the apply button. Applications must be received no later than 24 October 2021.


Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. 

Billions of people worldwide live with brain diseases – complex conditions often invisible to others that nonetheless take a tremendous toll on individuals, families and societies. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Every day, we strive for improved treatment and a better life for people living with brain disease.  

We have approximately 5,600 employees in more than 50 countries, and our products are available in more than 100 countries. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for which there are few, if any therapeutic options. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy. Lundbeck generated revenue of DKK 17.7 billion in 2020 (EUR 2.4 billion; USD 2.7 billion). 

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Instagram (h_lundbeck), Twitter at @Lundbeck and via LinkedIn.